10-K: Allurion wins FDA nod but faces delisting, cash crunch

Allurion secured FDA PMA approval for its swallowable gastric balloon but reported a 53% revenue decline, going‑concern doubts, NYSE delisting proceedings, and tight liquidity as it restructures and pursues financings.

Summary

• Revenue fell 53% to $15.23m in 2025 (2024: $32.11m); gross profit $9.57m (gross margin ~62.9%).
• Operating expenses declined 45% to $39.73m, driving a narrower operating loss of $30.16m (2024: $50.20m).
• Net loss was $28.76m (2024: $7.20m), with prior year aided by $43.72m other income from fair‑value gains.
• Cash and cash equivalents were $5.41m (plus $0.33m restricted) at 12/31/2025; cash used in operations was $28.95m.
• Total assets $15.77m vs. total liabilities $92.96m; stockholders’ deficit $(77.19)m; substantial doubt about going concern.
• Debt and financing obligations include $47.70m revenue interest financing and $28.07m (fair value) RTW convertible notes reclassified as current due to covenant non‑compliance.
• FDA granted PMA approval (2/20/2026) for the Allurion Gastric Balloon System; U.S. indication BMI 30–40, ages 22–65, up to two balloons over 10 months, avg residence ~15.3 weeks.
• NYSE commenced delisting (3/6/2026) after market cap fell below $15m; trading suspended and shares moved to OTC; appeal filed.
• France regulator (ANSM) lifted suspension (2/12/2025) after remediation; prior 8/6/2024 suspension triggered returns and halted sales in H2‑2024.
• Multiple 2025 equity raises and a 2/24/2026 warrant inducement generated ~$3.1m gross and created 5.32m new warrants at $1.15; a November 2025 exchange agreement would swap RTW notes/RIFAs into Series B preferred upon conditions.
• Workforce reduced by ~65% (approved 8/5/2025); employees at year‑end: 41 (31 U.S.).
• Vanderbilt lawsuit seeks ~$2.5m over clinical trial cost reimbursement; company intends to defend.

Sentiment

Score: 4

Explanation: StockSavvy.ai views FDA approval as a major milestone, but the sharp revenue decline, liquidity strain, going‑concern disclosure, covenant issues, and delisting proceedings weigh heavily on near‑term investment quality.

Positives

• FDA PMA approval (2/20/2026) for Allurion Gastric Balloon System enables U.S. commercialization with unique swallowable, procedureless profile.
• Operating expenses cut 45% YoY to $39.73m via restructuring; operating loss narrowed by $20.04m to $30.16m.
• Gross margin remained strong at ~62.9% in 2025 despite lower volume.
• ANSM lifted France suspension (2/12/2025), restoring a key market after remediation.
• Robust IP estate: 66 issued patents as of 12/31/2025 (23 U.S.; 43 OUS) plus pending applications.
• Clinical data: AUDACITY pivotal met responder endpoint; reported 3.1% SAE rate (lowest among U.S. pivotal liquid‑filled balloon trials cited).
• Multiple capital actions (Jan/Feb/Nov 2025 offerings, equity line, warrant inducement) provided ~$19m 2025 financing cash flow and $3.1m gross in Feb 2026.

Negatives

• Revenue down 53% to $15.23m; driven by reduced S&M investment, distributor transitions, France suspension, and tighter credit to customers.
• Going‑concern warning; cash $5.41m vs. operating cash burn of $28.95m and significant near‑term obligations.
• Large stockholders’ deficit $(77.19)m; total liabilities $92.96m.
• Non‑compliance with debt covenants; $28.07m fair value of RTW convertible notes reclassified as current.
• NYSE delisting proceedings; trading suspended and moved to OTC, impairing liquidity and institutional interest.
• Legal overhang: Vanderbilt claims ~$2.5m; outcome uncertain.
• Substantial dilution overhang: warrant repricings/inducement (5.32m new warrants at $1.15), multiple financings, and potential RTW exchange to preferred.

Risks

• Substantial doubt about ability to continue as a going concern given recurring losses, cash burn, and financing needs.
• Debt load and financing covenants (RTW notes and revenue interest financing) may restrict operations; non‑compliance could trigger adverse actions.
• NYSE delisting and OTC trading may depress trading liquidity, increase volatility, and hinder capital access.
• Commercial execution risk in the U.S. despite FDA approval; history of missing a primary superiority margin at 48 weeks in AUDACITY could affect adoption.
• Competition from GLP‑1 drugs and other devices; adherence, pricing, and side‑effect dynamics could impact demand.
• Supply chain concentration with single‑source suppliers may cause shortages or higher costs.
• Limited reimbursement; heavy reliance on cash‑pay models could be pressured by macroeconomic conditions.
• Regulatory exposure globally; prior France suspension highlights potential for sales disruption.
• Litigation risk, including Vanderbilt dispute (~$2.5m claim).
• Material weaknesses in internal controls and restatement history increase financial reporting risk.

Future Outlook

Management targets U.S. commercialization following FDA PMA approval, expects to leverage a cash‑pay model and its Virtual Care Suite, and continues cost controls from prior restructurings. Plans include pursuing the pending exchange of RTW obligations into preferred equity, additional capital sources as needed, post‑approval study commitments, and expansion of GLP‑1 combination evidence. Management previously indicated a focus on achieving EBITDA positivity in 2026, but this is contingent on financing and successful launch execution.

Management Comments

• Focus remains on U.S. launch and scaling the Allurion Program, including VCS and AI elements, following FDA approval.
• Operational efficiency initiatives and a significant reduction in general and administrative expenses are intended to accelerate the path to profitability.
• France remediation completed and authorization restored; global regulatory compliance and safety monitoring remain priorities.

Industry Context

StockSavvy.ai notes that obesity care is being reshaped by GLP‑1 therapies (Novo Nordisk, Eli Lilly) while devices and procedural options compete on safety, durability, and cost. Allurion’s swallowable, procedureless balloon is differentiated versus U.S. balloons from Boston Scientific (ORBERA) and Spatz that require endoscopy/anesthesia. However, GLP‑1 adoption and cash‑pay economics pressure demand. FDA approval creates a first‑mover U.S. niche, but sustained uptake will hinge on pricing, outcomes, and distribution efficiency.

Comparison to Industry Standards

• Compared to endoscopic balloons (e.g., ORBERA, Spatz), Allurion’s swallowable design avoids anesthesia/endoscopy, potentially lowering SAE exposure and procedural burden.
• Allurion reports a 3.1% SAE rate in its pivotal vs. cited 7–10% SAE rates in historic U.S. balloon trials (ReShape/Apollo) for liquid-filled balloons; direct head‑to‑head data remain absent.
• GLP‑1 competitors (Novo Nordisk’s semaglutide, Eli Lilly’s tirzepatide) have superior average weight loss but face adherence, cost, and muscle loss concerns; Allurion positions for combination or second‑line use.
• Commercial scale lags sector leaders; unlike Boston Scientific’s breadth and channel access, Allurion must build U.S. distribution post‑PMA while managing liquidity constraints.
• Financial resilience is below medtech norms: stockholders’ deficit $(77.19)m and going‑concern risk contrast with peer balance sheets, increasing execution risk.

Management Changes

Corporate Governance

Legal Proceedings

• Vanderbilt University Medical Center v. Allurion Technologies, Inc. (filed 08/12/2025): breach of Clinical Trial Agreement alleged; damages sought approximately $2.5 million; company intends to defend.

Related Party Transactions

• RTW: $48m convertible notes (04/16/2024), revenue interest financings ($40m initial; $7.5m additional on 10/30/2024), private placements (multiple) and board designation rights.
• Remus Group/affiliates and KKG Enterprises: prior consulting arrangements in early 2023 for AI/platform advisory and Business Combination support; subsequently terminated.
• French office lease through an entity partially owned by former executive; terminated February 2024.

Stakeholder Impact

• Shareholders: dilution risk from repeated equity issuances and warrant inducements; delisting to OTC may reduce liquidity and valuation.
• Employees: workforce reduction (~65%) and tight liquidity create uncertainty but may improve cost structure.
• Customers/providers: FDA approval expands U.S. access; prior France suspension resolved; continued product availability in >50 countries.
• Suppliers: single‑source dependencies elevate continuity risk amid cash constraints.
• Creditors: covenant non‑compliance and exchange proposal to preferred indicate restructuring of capital stack.

Next Steps

• Initiate and scale U.S. commercialization of the PMA‑approved Allurion Gastric Balloon System.
• Complete post‑approval study obligations and ongoing safety surveillance.
• Pursue successful appeal of NYSE delisting or optimize OTC listing tier and liquidity.
• Close the RTW exchange into Series B Preferred Stock upon satisfying listing and other conditions.
• Continue cost controls and cash collections; evaluate additional capital options.
• Advance GLP‑1 combination clinical validation and provider education for B2B2C model.

Key Dates

Recommendation

Despite a strategically important FDA approval, the filing details a 53% revenue decline, severe liquidity constraints, going‑concern doubts, debt covenant breaches, stockholders’ deficit, and NYSE delisting proceedings. The near‑term financing overhang and execution risks outweigh the approval catalyst, making the risk‑reward unfavorable.

Keywords

Allurion, ALUR, swallowable gastric balloon, intragastric balloon, Allurion Smart Capsule, PMA approval, weight loss device, GLP-1 combination, Virtual Care Suite, RTW convertible notes, revenue interest financing, NYSE delisting, OTC Markets, reverse stock split, obesity treatment